FDA Grants Approval for Everolimus ANDA219464
The FDA has granted approval for the ANDA219464 application for Everolimus submitted by I3 PHARMS.
Asset / Drug
Drug and asset intelligence for Everolimus with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
mTOR Inhibitor
No catalysts indexed for this entity yet.
July 3, 2026 · N/A
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.